By using immunohistochemistry on tissue microarrays, we evaluated whether subcellular localization and expression of FTH1 in 222 BCs of BRCA1/2 mutation carriers were associated with clinical outcome after BC. This evidence concerns the gene BRCA1 and breast cancer.